Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-23 7:40 pm Sale | 2024-09-30 | 13G | Creative Realities, Inc. CREX | Lytton, Laurence W. | 784,000 7.500% | -268,204 (-25.49%) | Filing History |
| 2024-10-23 7:39 pm Purchase | 2023-12-31 | 13G | Creative Realities, Inc. CREX | Lytton, Laurence W. | 1,052,204 10.100% | 11,000 (+1.06%) | Filing History |
| 2024-10-23 7:38 pm Purchase | 2023-12-04 | 13G | Creative Realities, Inc. CREX | Lytton, Laurence W. | 1,041,204 10.000% | 41,204 (+4.12%) | Filing History |
| 2024-10-23 7:37 pm Purchase | 2023-08-18 | 13G | Creative Realities, Inc. CREX | Lytton, Laurence W. | 1,000,000 9.600% | 1,000,000 (New Position) | Filing History |
| 2024-10-04 5:14 pm Purchase | 2024-09-26 | 13G | MDxHealth S.A. MDXH | Lytton, Laurence W. | 2,890,595 6.100% | 2,890,595 (New Position) | Filing History |
| 2024-07-22 3:20 pm Purchase | 2024-07-10 | 13G | TELA Bio, Inc. TELA | Lytton, Laurence W. | 1,340,052 5.400% | 1,340,052 (New Position) | Filing History |
| 2024-07-08 12:48 pm Purchase | 2024-06-27 | 13G | CalciMedica, Inc. CALC | Lytton, Laurence W. | 756,180 6.900% | 756,180 (New Position) | Filing History |
| 2024-05-17 5:20 pm Purchase | 2024-05-09 | 13G | Acutus Medical, Inc. AFIB | Lytton, Laurence W. | 1,746,823 5.900% | 1,746,823 (New Position) | Filing History |
| 2024-04-29 2:34 pm Purchase | 2024-04-17 | 13G | scPharmaceuticals Inc. SCPH | Lytton, Laurence W. | 1,825,234 5.100% | 1,825,234 (New Position) | Filing History |
| 2024-03-20 1:00 pm Purchase | 2024-02-20 | 13G | Biofrontera Inc. BFRI | Lytton, Laurence W. | 508,886 9.990% | 508,886 (New Position) | Filing History |
| 2024-03-13 1:32 pm Purchase | 2024-02-09 | 13G | Evoke Pharma, Inc. EVOK | Lytton, Laurence W. | 71,610 9.990% | 71,610 (New Position) | Filing History |
| 2024-02-27 2:05 pm Purchase | 2024-02-14 | 13G | Azitra, Inc. AZTR | Lytton, Laurence W. | 369,985 5.800% | 369,985 (New Position) | Filing History |
| 2024-02-14 6:48 pm Sale | 2023-12-31 | 13G | TFF Pharmaceuticals, Inc. TFFP | Lytton, Laurence W. | 11,900 0.100% | -113,129 (-90.48%) | Filing History |
| 2024-02-14 3:28 pm Purchase | 2023-12-31 | 13G | Scientific Industries, Inc. SCND | Lytton, Laurence W. | 1,083,899 9.990% | 689,220 (+174.63%) | Filing History |
| 2024-02-14 3:23 pm Purchase | 2023-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Lytton, Laurence W. | 109,339 9.990% | 46,504 (+74.01%) | Filing History |
| 2024-02-14 2:42 pm Purchase | 2023-12-31 | 13G | Exagen Inc. XGN | Lytton, Laurence W. | 1,153,488 6.800% | 282,307 (+32.41%) | Filing History |
| 2024-02-14 2:35 pm Purchase | 2023-12-31 | 13G | Stryve Foods, Inc. SNAX | Lytton, Laurence W. | 194,780 8.900% | 194,780 (New Position) | Filing History |
| 2024-02-14 2:27 pm Purchase | 2023-12-31 | 13G | Societal CDMO, Inc. SCTL | Lytton, Laurence W. | 10,340,858 9.900% | 3,847,168 (+59.24%) | Filing History |
| 2024-02-14 2:22 pm Purchase | 2023-12-31 | 13G | Rail Vision Ltd. RVSN | Lytton, Laurence W. | 450,000 9.300% | 252,500 (+127.85%) | Filing History |
| 2024-02-14 2:09 pm Purchase | 2023-12-31 | 13G | RingCentral, Inc. RNG | Lytton, Laurence W. | 1,528,157 1.800% | 1,528,157 (New Position) | Filing History |